TKM-080301

DRUG3 trials

Sponsors

Arbutus Biopharma Corporation, National Cancer Institute (NCI)

Conditions

ACCAdrenocortical CarcinomaBreast Cancer With Hepatic MetastaseCancerColorectal Cancer With Hepatic MetastasesGastric Cancer With Hepatic MetastaseHepatocellular CarcinomaHepatoma

Phase 1

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

CompletedNCT01262235

Arbutus Biopharma CorporationACC, Adrenocortical Carcinoma, Cancer +2

Start: 2010-12-31End: 2015-08-31Updated: 2019-01-16

TKM 080301 for Primary or Secondary Liver Cancer

CompletedNCT01437007

National Cancer Institute (NCI)Breast Cancer With Hepatic Metastase, Colorectal Cancer With Hepatic Metastases, Gastric Cancer With Hepatic Metastase +2

Start: 2011-08-26End: 2012-06-21Updated: 2018-08-03

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

CompletedNCT02191878

Arbutus Biopharma CorporationHepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult +1

Start: 2014-06-30End: 2016-07-31Updated: 2019-01-16

Related Papers

A phase I/II study of TKM-080301, a <i>PLK1</i>-targeted RNAi in patients with adrenocortical cancer (ACC).

Journal of Clinical Oncology2016-05-2049 citations